- Record: found
- Abstract: found
- Article: not found
Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial.
Arthur M Pancioli
1 ,
Opeolu Adeoye ,
Pamela A Schmit ,
Jane Khoury ,
Steven R Levine ,
Thomas A Tomsick ,
Heidi Sucharew ,
Claudette E Brooks ,
Todd J Crocco ,
Laurie Gutmann ,
Thomas M Hemmen ,
Scott E Kasner ,
Dawn Kleindorfer ,
William A Knight ,
Sharyl Martini ,
James S McKinney ,
William J Meurer ,
Brett C Meyer ,
Alexander Schneider ,
Phillip A Scott ,
Sidney Starkman ,
Steven Warach ,
Joseph P Broderick
Sep 2013
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
In a previous study, 0.3 and 0.45 mg/kg of intravenous recombinant tissue plasminogen activator (rt-PA) were safe when combined with eptifibatide 75 mcg/kg bolus and a 2-hour infusion (0.75 mcg/kg per minute). The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke-Enhanced Regimen (CLEAR-ER) trial sought to determine the safety of a higher-dose regimen and to establish evidence for a phase III trial.